At a glance

ClinicalIndex Comparison Record

Phase 1Completed· 75 enrolled

Drug / intervention

Bococizumab (PF-04950615; RN316) +2 morebiological

Likely dose

Bococizumab (PF-04950615; RN316) 150 mgfrom record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02043301

NCT02043301Phase 1Completed

Compare CT.gov

A PHASE 1, OPEN-LABEL, RANDOMIZED, SINGLE DOSE, PARALLEL GROUP STUDY TO ASSESS INJECTION SITE RELATIVE BIOAVAILABILITY OF PF-04950615 FOLLOWING SUBCUTANEOUS ADMINISTRATION IN ADULT SUBJECTS WITH HYPERCHOLESTEROLEMIA

Pfizer·interventional·Posted Jan 23, 2014·Updated May 31, 2019

In Brief

A Phase 1 clinical trial evaluating Bococizumab (PF-04950615; RN316) for Hypercholesterolemia. Completed, enrolled 75 participants across 6 sites.

Detailed Summary

This study aims to characterize the single dose pharmacokinetics of PF-04950616 following subcutaneous injection to the abdomen, upper arm or the thigh.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsHypercholesterolemia

CountriesUnited States

Collaborators--

Timeline

Phase 1CompletedFinished

2014201520162017201820192020202120222023202420252026

First PostedJan 2014

Enrollment StartApr 2014

Primary CompletionNov 2014

TodayJul 2026

First PostedJan 23, 2014

Enrollment StartApr 1, 2014

Primary CompletionNov 1, 2014

TodayJul 2, 2026

Enrollment to primary: 7 monthsPosted 12.4 years ago

Interventions

Bococizumab (PF-04950615; RN316)biological

Single 150 mg PF-04950615 dose administered SC to the abdomen

Bococizumab (PF-04950615; RN316)biological

Single 150 mg PF-04950615 dose administered SC to the upper arm

Bococizumab (PF-04950615; RN316)biological

Single 150 mg PF-04950615 dose administered SC to the thigh